ClinicalTrials.gg
RecruitingNCT07371455Updated Mar 20, 2026

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants

A Phase 1 interventional study of LWP779 and Placebo of LWP779 in Ischemic Stroke, sponsored by Longwood Pharmaceuticals (Hangzhou) Co., Ltd.. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by Longwood Pharmaceuticals (Hangzhou) Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies in Ischemic Stroke with a site in Australia — 17 open to participants now, 20 under way, 8 of them phase 3. Ischemic Stroke · Australia.

Planned enrollment
46th of 55
76 · median 300
Started
2026
with 2 others
Phase 1
3 of 62
1 open now
Primary completion
2026-07
later than 2 of 19 live
Registered
61st of 62
by date

Among the 62 studies in Ischemic Stroke with a site in Australia, this one is the 46th largest by planned enrollment of the 55 interventional ones that give a count, is one of 3 that started in 2026, is one of 3 in phase 1, reaches primary completion later than 2 of the 19 other live ones, and was the 61st registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

17 of the 62 studies in Ischemic Stroke with a site in Australia are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Ischemic Stroke with a site in Australia, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, placebo-controlled clinical trial featuring both single ascending dose (SAD), food effect and multiple ascending dose (MAD) phases intended to evaluate the safety, tolerability, PK, PD, and active metabolites of LWP779 after oral administration in healthy participants.

03

Conditions studied

  • Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Capable of understanding the written document; willingly provides valid, signed written informed consent;
  • 2. Males and females aged 18 to 65 years old (inclusive) at the time of signing the ICF.
  • 3.No history of past or current diseases or abnormalities involving the cardiac, hepatic, renal, gastrointestinal, nervous, respiratory, or ocular systems, as well as psychiatric or metabolic abnormalities, that are as judged by the investigator.
  • 4.Participants must be confirmed healthy through medical history, VS, physical examination, clinical laboratory tests , and a 12-lead ;
  • 5. (BMI) of 18.0 to 32.0 kg/m2 inclusive and body weight not less than 50 kg at the time of screening and Day -1.
  • 6. Participants must agree to take the investigator-approved effective measures during the trial as required by the investigator.
  • 7.Normal renal function (defined as ≥ 80 mL/min/1.73 m2) at screening and Day -1.
  • 8. Ability to swallow and retain oral medication.
  • 9.No suicidal ideation, as demonstrated by a score of "0" on the Columbia Suicide Severity Rating Scale (C-SSRS) at screening or Day -1.

Exclusion criteria

Exclusion Criteria:

  • 1.Known to LWP779 or any of its constituents.
  • 2.Known or suspected tumor.
  • 3.History of unexplained syncope, symptomatic hypotension or hypoglycemia.
  • 4.Presence of orthostatic hypotension at screening or Day -1.
  • 5.Participants with any ocular diseases (e.g., glaucoma, fundus macular degeneration, corneal lesions, retinopathy, etc.).
  • 6.Family history of long syndrome; mean QTcF interval >450 msec for males and >470 msec for females or presence of any other mean abnormality at screening or Day -1 deemed by the PI/medical delegate.
  • 7.Resting pulse rate \<45 bpm or >100 bpm at screening, or Day -1.
  • 8.Systolic blood pressure \< 90 or >160 mm Hg and/or diastolic blood pressure \< 50 or > 95 mm Hg at screening or Day -1.
  • 9.History of unstable ischemic heart disease, recent (within 6 months of screening) myocardial infarction, or presence of clinically significant cardiac arrhythmia.
  • 10.Ongoing liver disease or unexplained liver function test (LFT) elevations, defined as , AST, gamma glutamyl transferase (GGT), alkaline phosphatase (ALP) or total/direct > 1.5x at screening or Day -1. Participants with confirmed Gilbert's syndrome will not be permitted to enroll in the study.
  • 11.History of chronic diarrhea, malabsorption, unexplained weight loss, food allergies or intolerance deemed clinically significant by the PI/medical delegate.
  • 12.History of cerebral hemorrhage (e.g., post-traffic accident), stroke, or cerebrovascular disease.
  • 13.Participants judged by the PI/medical delegate to have any condition or history that may alter or increase bleeding tendency.
  • 14.Participants regularly using drugs affecting coagulation function within 3 months before screening, or had received anticoagulant therapy such as heparin, low-molecular-weight heparin, fibrinolytic agents, etc. in the same timeframe.
  • 15.Participants with conditions that may, in the opinion of the PI/medical delegate, significantly affect normal venous blood collection.
  • 16.Positive results for (HIV) antibody, surface antigen (HBsAg), or virus (HCV) antibody at screening.
  • 17.Donated or lost >500 ml of blood in the previous 3 months prior to screening, donation of bone marrow or peripheral stem cells within 90 days prior to Day 1, or donation of plasma within 30 days prior to Day 1.
  • 18.Participants who have participated in any drug study within the past 3 months or 5 half-lives (whichever is longer) prior to dosing, or have participated in any investigational device study within the past 3 months prior to dosing.
  • 19.Previous exposure to LWP779.
  • 20.Use of prescription medications, vaccination, or any drugs known to induce or inhibit /5 or P-glycoprotein within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study drug.
  • 21.Use of over-the-counter (OTC) medication or supplements (including vitamins, dietary supplements, herbal medicines, homoeopathy, etc.) within 14 days or 5 half-lives (whichever is longer), prior to receiving the first dose of study drug that might have impact on the clinical trial as per the PI/medical delegate's discretion. Acetaminophen (paracetamol) is permitted if provided maximum daily dose does not exceed 2000 mg.
  • 22.Hospital admission or major surgery within 6 months prior to screening, or history of bariatric surgery.
  • 23.A history of prescription drug misuse (as assessed by the PI/medical delegate), or positive urine drug screen at screening or Day -1.
  • 24.Regular consumption of more than 10 standard alcoholic drinks per week or more than 4 standard alcoholic drinks on any one day, where 1 standard drink is 10 g of pure alcohol and is equivalent to 285 mL beer [4.9% Alc/Vol], 100 mL wine [12% Alc/Vol], or 30 mL spirit [40% Alc/Vol]).
  • 25.Consumes more than 2 cigarettes or equivalent nicotine-containing products per week, and/or is unwilling to abstain from the use of such products for 7 days prior to Day -1 through to EOS. Positive cotinine test at Day -1.
  • 26.Use of cannabis or cannabidiol (CBD) containing products, in any form (e.g., edibles, oil, lotion, smoking) within 30 days prior to study drug administration on Day 1, regardless of legality within a given State, County or Region.
  • 27.Participant is pregnant (as determined by pregnancy test result at screening or Day -1) or breastfeeding.
  • 28.Participants who had consumed any food or beverage containing caffeine, alcohol, xanthine, Seville orange, pomelo, dragon fruit, starfruit, guava or grapefruit within 48 hours before each admission to the CRU.
  • 29.A positive screen for alcohol at screening or Day -1.
  • 30.Employee or family member of the Investigator (PI/medical delegate), study site personnel, or sponsor.
  • 31.Food Effect study part only: unwilling to consume a high-fat meal consisting of eggs, bacon, butter, white bread and full cream milk.
  • 32.Unable or unwilling to comply with the study restrictions and requirements
  • 33.Participant developed an acute condition during the screening phase or before administration of the study drug; any other condition or finding that in the PI/medical delegate's opinion would put the participant or study conduct at risk if the participant were to be included in the study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    Single Ascending Dose - 150 mg

    Drug: LWP779 · Drug: Placebo of LWP779

  • Experimental
    Single Ascending Dose - 300 mg

    Drug: LWP779 · Drug: Placebo of LWP779

  • Experimental
    Single Ascending Dose - 600 mg

    Drug: LWP779 · Drug: Placebo of LWP779

  • Experimental
    Single Ascending Dose - 900 mg

    Drug: LWP779 · Drug: Placebo of LWP779

  • Experimental
    Single Ascending Dose - 1200 mg

    Drug: LWP779 · Drug: Placebo of LWP779

Interventions

  • DrugLWP779

    Active

  • DrugPlacebo of LWP779

    Placebo

06

What researchers measure

Primary outcomes

  1. Number and proportion of participants with a treatment-emergent adverse event (TEAE)

    Time frame: From baseline to Day 7 (±1) for SAD, baseline to Day16 (±2) for FE, baseline to Day 14 (± 2) for MAD

  2. 12-lead electrocardiogram (ECG) (QT Interval)

    Time frame: From baseline to Day 7 (±1) for SAD, baseline to Day16 (±2) for FE, baseline to Day 14 (± 2) for MAD

  3. Number of participants with abnormal vital signs

    Time frame: From baseline to Day 7 (±1) for SAD, baseline to Day16 (±2) for FE, baseline to Day 14 (± 2) for MAD

  4. Number of participants with abnormal physical examination findings

    Time frame: From baseline to Day 7 (±1) for SAD, baseline to Day16 (±2) for FE, baseline to Day 14 (± 2) for MAD

  5. Columbia Suicide Severity Rating Scale (C-SSRS)

    The Columbia Suicide Severity Rating Scale (C-SSRS) is used to assess suicidal ideation and suicidal behavior. Within the module "Answer for Actual Suicidal Attempts Only", the scoring range is 0 to 5. A score of 0 indicates no physical damage or very minor physical damage (e.g. surface scratches), and a score of 5 indicates death.

    Time frame: From baseline to Day 7 (±1) for SAD, baseline to Day16 (±2) for FE, baseline to Day 14 (± 2) for MAD

  6. Number of participants with abnormal laboratory tests results

    Time frame: From baseline to Day 7 (±1) for SAD, baseline to Day16 (±2) for FE, baseline to Day 14 (± 2) for MAD

  7. Number of participants with abnormal ophthalmoscopic-examination findings

    Time frame: From baseline to Day 7 (±1) for SAD, baseline to Day16 (±2) for FE, baseline to Day 14 (± 2) for MAD

Secondary outcomes

  1. C-QTc in the dose escalation part of SAD(in the dose groups of ≥300 mg)

    Time frame: Wthin 30 minutes before administration and to 24 hours after administration.

  2. Maximum concentration (Cmax) of LWP779 and its active metabolites in plasma

    Time frame: Within 30 minutes before administration to 48 hours after single administration

  3. Time to reach Cmax (Tmax) of LWP779 and its active metabolites in plasma

    Time frame: Within 30 minutes before administration to 48 hours after single administration

  4. Total area under the concentration time curve (AUC) of LWP779 and its active metabolites in plasma

    Time frame: Within 30 minutes before administration to 48 hours after single administration

  5. Apparent terminal half-life (t1/2) of LWP779 and its active metabolites in plasma

    Time frame: Within 30 minutes before administration to 48 hours after single administration

  6. Terminal elimination rate constant (λz) of LWP779 and its active metabolites in plasma

    Time frame: Within 30 minutes before administration to 48 hours after single administration

  7. Apparent clearance (CL/F) of LWP779 and its active metabolites in plasma

    Time frame: Within 30 minutes before administration to 48 hours after single administration

  8. Apparent volume of distribution divided by bioavailability (Vd/F) of LWP779 and its active metabolites in plasma

    Time frame: Within 30 minutes before administration to 48 hours after single administration

  9. Lag time (tlag) of LWP779 and its active metabolites in plasma

    Time frame: Within 30 minutes before administration to 48 hours after single administration

  10. Steady-state minimum concentration (Cmin,ss) of LWP779 and its active metabolites in plasma

    Time frame: Wthin 30 minutes before administration to 24 hours after multiple administration on Day 1 and Day 7, and 30 min pre-dose on Day 5 and Day 6.

  11. Steady-state maximum concentration (Cmax,ss) of LWP779 and its active metabolites in plasma

    Time frame: Wthin 30 minutes before administration to 24 hours after multiple administration on Day 1 and Day 7, and 30 min pre-dose on Day 5 and Day 6.

  12. Steady-state average concentration (Cavg,ss) of LWP779 and its active metabolites in plasma

    Time frame: Wthin 30 minutes before administration to 24 hours after multiple administration on Day 1 and Day 7, and 30 min pre-dose on Day 5 and Day 6.

  13. Area under the concentration-time curve from time zero to tau (AUC0-τ) of LWP779 and its active metabolites in plasma

    Time frame: Wthin 30 minutes before administration to 24 hours after multiple administration on Day 1 and Day 7, and 30 min pre-dose on Day 5 and Day 6.

  14. Time to reach Cmax (Tmax) of LWP779 and its active metabolites in plasma

    Time frame: Wthin 30 minutes before administration to 24 hours after multiple administration on Day 1 and Day 7, and 30 min pre-dose on Day 5 and Day 6.

  15. Terminal elimination rate constant (λz) of LWP779 and its active metabolites in plasma

    Time frame: Wthin 30 minutes before administration to 24 hours after multiple administration on Day 1 and Day 7, and 30 min pre-dose on Day 5 and Day 6.

  16. Apparent terminal half-life (t1/2) of LWP779 and its active metabolites in plasma

    Time frame: Wthin 30 minutes before administration to 24 hours after multiple administration on Day 1 and Day 7, and 30 min pre-dose on Day 5 and Day 6.

  17. Accumulation index (AUC0-τ (D7) / AUC0-τ (D1)) of LWP779 and its active metabolites in plasma

    Time frame: Wthin 30 minutes before administration to 24 hours after multiple administration on Day 1 and Day 7, and 30 min pre-dose on Day 5 and Day 6.

  18. Cmax (D7) / Cmax (D1)) of LWP779 and its active metabolites in plasma

    Time frame: Wthin 30 minutes before administration to 24 hours after multiple administration on Day 1 and Day 7, and 30 min pre-dose on Day 5 and Day 6.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jul 2026, 3 months after the start.

Of 42 phase 1 interventional studies under Ischemic Stroke, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's planned 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 25, 2025
First posted
Jan 28, 2026
StartActual
Mar 13, 2026
Primary completionEst.
Jul 10, 2026
CompletionEst.
Sep 30, 2026
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07371455
Lead sponsor
Longwood Pharmaceuticals (Hangzhou) Co., Ltd.
Responsible party
Sponsor
First posted
Jan 28, 2026
Start date
Mar 13, 2026
Primary completion
Jul 10, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Mar 20, 2026

Study contacts

Tingting Yan
Contact
tingting.yan1@longwoodtech.com
+86 15989276332

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion